UNSPSC 51151635: Gallamine

This classification denotes an anticholinergic agent with the molecular formula C24H45N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1146X1WTNM, chemically known as 1,2,3-trihydroxybenzene but generally known as gallamine, which bears US NIH Compound Identifier 1057. European Medicines Agency schedules Gallamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02305MIG. World Health Organization schedules gallamine in its Anatomical Therapeutic Chemical (ATC) Classification.

GALLAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, GALLAMINE remains the US FDA Preferred Term for this commodity. Gallamine bears US NLM identifiers UMLS ID C0016971 and NCI Concept Code C87604. SMILES: OC1C(O)CCCC1O..

UNSPSC 51151635 Gallamine is a Commodity code that in recent state and local procurement activity encompasses naloxone and drug deactivation systems for community health and emergency response purposes. State and local governments buying under this code are acquiring pharmaceutical products and related safety equipment to support overdose intervention and controlled substance disposal programs. The issuing bodies include county health departments and state health and human services agencies, both pursuing supply agreements that involve recurring annual volumes with multi-year contract terms and renewal options.

The geographic spread of recent activity includes Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023; the contract carries a two-year initial term with one-year renewal option and is potentially funded through FEMA, imposing additional federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's interest in direct contracting models for pharmaceutical procurement outside traditional pharmacy benefit manager and group purchasing organization channels. Both solicitations emphasize fixed-fee or negotiated pricing, vendor insurance and compliance certifications, and delivery responsibility included in the proposal.